HOB BIOTECH(SH:688656)2025-02-26 09:55Financial Performance - Total revenue for 2024 reached RMB 402.31 million, a 2.00% increase compared to RMB 394.41 million in the previous year[3] - Operating profit decreased by 25.88% to RMB 41.39 million from RMB 55.84 million year-on-year[3] - Net profit attributable to shareholders decreased by 22.15% to RMB 36.85 million from RMB 47.33 million in the previous year[3] - Basic earnings per share decreased by 21.33% to RMB 0.59 from RMB 0.75 in the previous year[3] Assets and Equity - Total assets increased by 8.77% to RMB 1,032.50 million from RMB 949.26 million at the beginning of the period[3] - The company's equity attributable to shareholders increased by 0.18% to RMB 812.18 million from RMB 810.73 million at the beginning of the period[3] Business Strategy - The company plans to continue strengthening its main business in allergy and autoimmune diagnostics, with increased investment in new product development and technology[8] - The company aims to optimize supply chain management and enhance cost efficiency to improve core competitiveness and profitability[9] Non-Operating Income - The increase in non-operating income was affected by reduced returns from bank financial products compared to the previous year[10] Financial Reporting - The financial data presented is preliminary and subject to change upon final audit in the annual report[11]